PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference
PMV Pharmaceuticals (Nasdaq: PMVP) announced that CEO David H. Mack, Ph.D., will present at the Bank of America Healthcare Conference on May 13, 2021, at 12:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PMV Pharmaceuticals (Nasdaq: PMVP) announced that CEO David H. Mack, Ph.D., will present at the Bank of America Healthcare Conference on May 13, 2021, at 12:30 PM ET. The presentation will discuss PMV's pioneering work in precision oncology and its focus on developing small molecule therapies targeting p53 mutants, which are prevalent in about half of all cancers. The company will also engage in one-on-one meetings with investors during the conference. A replay of the presentation will be accessible on PMV's website.
Details
News Market Reaction – PMVP
The recorded move for PMVP in the trading session of this news was +0.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will present at the Bank of America Healthcare Conference on Thursday, May 13, 2021. The company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
| Bank of America Healthcare Conference | |
| Date: | Thursday, May 13, 2021 |
| Time: | 12:30 PM ET |
| Webcast: | http://www.veracast.com/webcasts/bofa/hc2021/idMy79HJ.cfm |
A replay of the presentation will be available by visiting the “Events & Presentations” section of the PMV Pharmaceuticals website.
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Contact
For Investors & Media:
Winston Kung
Chief Financial Officer
investors@pmvpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.